AR111410A1 - SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS INHIBITORS OF PROTEIN KINASES - Google Patents

SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS INHIBITORS OF PROTEIN KINASES

Info

Publication number
AR111410A1
AR111410A1 ARP180100851A ARP180100851A AR111410A1 AR 111410 A1 AR111410 A1 AR 111410A1 AR P180100851 A ARP180100851 A AR P180100851A AR P180100851 A ARP180100851 A AR P180100851A AR 111410 A1 AR111410 A1 AR 111410A1
Authority
AR
Argentina
Prior art keywords
splice variant
nucleic acid
chemotherapeutic agents
gene
protein kinases
Prior art date
Application number
ARP180100851A
Other languages
Spanish (es)
Inventor
Shikha Saini
Fei Yue
Aditi Mathur
Sidney Hopps
Bellur Prabhakar
Original Assignee
Jivana Biotechnology Inc
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jivana Biotechnology Inc, Univ Illinois filed Critical Jivana Biotechnology Inc
Publication of AR111410A1 publication Critical patent/AR111410A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones y métodos para tratar cánceres, que comprenden administrar una combinación de agentes antineoplásicos, donde la combinación comprende agentes quimioterapéuticos inhibidores de proteína quinasas y una o más moléculas de ácidos nucleicos capaces de regular negativamente la expresión de al menos una variante de empalme del gen IG20, donde no todas las variantes de empalme del gen IG20 son reguladas negativamente. En una forma de realización, la variante de empalme del gen IG20 es una variante de empalme MADD y las moléculas de ácidos nucleicos son siARN, ARNhc y oligonucleótidos antisentido que comprenden una secuencia de ácido nucleico complementaria de la secuencia de ácido nucleico del exón 13L de la variante de empalme MADD o un transcripto de ARNm del exón 13L de la variante de empalme MADD. Métodos para tratar cánceres donde se aplica una terapia combinada con moléculas de ácidos nucleicos capaces de regular negativamente la expresión de al menos una variante de empalme del gen IG20 y agentes quimioterapéuticos inhibidores de proteína quinasas.Compositions and methods for treating cancers, comprising administering a combination of antineoplastic agents, wherein the combination comprises chemotherapeutic agents that inhibit protein kinases and one or more nucleic acid molecules capable of negatively regulating the expression of at least one splice variant of the IG20 gene , where not all splice variants of the IG20 gene are negatively regulated. In one embodiment, the splice variant of the IG20 gene is a MADD splice variant and the nucleic acid molecules are siRNA, hRNA and antisense oligonucleotides comprising a nucleic acid sequence complementary to the exon 13L nucleic acid sequence of the MADD splice variant or an exon 13L mRNA transcript of the MADD splice variant. Methods to treat cancers where a combination therapy with nucleic acid molecules capable of negatively regulating the expression of at least one splice variant of the IG20 gene and protein kinase inhibitor chemotherapeutic agents is applied.

ARP180100851A 2017-04-24 2018-04-05 SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS INHIBITORS OF PROTEIN KINASES AR111410A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762489050P 2017-04-24 2017-04-24

Publications (1)

Publication Number Publication Date
AR111410A1 true AR111410A1 (en) 2019-07-10

Family

ID=63919941

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100851A AR111410A1 (en) 2017-04-24 2018-04-05 SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS INHIBITORS OF PROTEIN KINASES

Country Status (3)

Country Link
AR (1) AR111410A1 (en)
TW (1) TW201902487A (en)
WO (1) WO2018200149A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004012769A1 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
WO2007084954A2 (en) * 2006-01-19 2007-07-26 The Board Of Trustees Of The University Of Illinois Selective inhibition of ig20 splice variants to treat cancers
WO2010006239A2 (en) * 2008-07-10 2010-01-14 The Board Of Trustees Of The University Of Illinois Regulation of apoptosis by neural specific splice variants of ig20

Also Published As

Publication number Publication date
WO2018200149A1 (en) 2018-11-01
TW201902487A (en) 2019-01-16

Similar Documents

Publication Publication Date Title
MX2018013157A (en) Oligonucleotide analogues targeting human lmna.
CO2020001354A2 (en) Methods and compositions for treating a bleeding event in a subject suffering from hemophilia an RNA, for example, a double-stranded ribonucleic acid (rnhd), compositions targeting the serinc1 gene, and methods for using said RNA, for example, rnhd, compositions for treat a bleeding event in a subject who has hemophilia (eg, with or without inhibitors).
CL2017001956A1 (en) Tau antisense oligomers and their use
CY1122583T1 (en) PROTEASOME INHIBITORS FOR THE TREATMENT OF A DISORDER ASSOCIATED WITH AN ACCUMULATION OF AN UNDESTRUCTED ABNORMAL PROTEIN OR A CANCER
CL2021002326A1 (en) rni anti-angiotensinogen (agt) compositions and methods for their use (divisional application no. 202002865)
CL2020002563A1 (en) Use of fubp1 inhibitors for the treatment of hepatitis b virus infection
AR090641A1 (en) COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GEN ALAS1
NZ733882A (en) Compositions for modulating c9orf72 expression
WO2013086444A3 (en) Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
BR112017018329A2 (en) DPP-4 prevention or treatment composition for the calcification of the valve containing the inhibitor
CL2021001490A1 (en) Chemically Modified Iarn Constructs and Uses of These
SG11201907581VA (en) Hexokinase 2-specific inhibitors for use in acute central nervous system injury
CL2021001552A1 (en) Inhibitory double-stranded nucleic acid molecules containing a triloop
PE20230993A1 (en) IARN CONSTRUCTS AND METHODS TO INHIBIT THE EXPRESSION OF MARC1
BR112017018198A2 (en) inhibition of olig2 activity
ZA201901367B (en) Inhibition of olig2 activity
MX2022009870A (en) Rnas for complement inhibition.
CL2021000018A1 (en) Oligonucleotides to modulate the expression of rtel1
BR112022008295A2 (en) COMBINED INHIBITION OF PD-1, TGFBETA AND TIGIT FOR THE TREATMENT OF CANCER
MX2021013418A (en) Double-stranded nucleic acid inhibitor molecules with shortened sense strands.
AR111410A1 (en) SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS INHIBITORS OF PROTEIN KINASES
EA201792406A1 (en) ANTI-SEMANTIC OLIGONUCLEOTIDE FOR THE TREATMENT OF DYSTROPHIC BULSE EPIDERMOLYSIS
MX2022002995A (en) Treatment of hidradenitis with jak inhibitors.
AR111587A1 (en) SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND RENTING CHEMOTHERAPEUTIC AGENTS
AR111409A1 (en) SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS OF ANTHRACICLINES

Legal Events

Date Code Title Description
FB Suspension of granting procedure